Research Paper Volume 13, Issue 21 pp 24136—24154
Mutations in DNA damage response pathways as a potential biomarker for immune checkpoint blockade efficacy: evidence from a seven-cancer immunotherapy cohort
Figure 4. Association of DDR mutations with survival outcome in distinct clinical settings based on the data from MSKCC and TCGA cohorts. HR value, 95% CI, and P value were derived from multivariate Cox regression model with clinical factors adjusted. *P < 0.05; **P < 0.01; ***P < 0.001.